In line with an exclusive UK/US distribution agreement of December 2019 to expand into the UK, the product has been manufactured and will be exported under licence to the UK.
The first order of 5,000 units is awaiting an 'ex-works' collection
Part of the agreement was the supply of a cannabinoid product combining Mg Optima Relax, a current Medlab nutraceuticals formulation available in Australian pharmacies and CBD that is used in the NanoCBD™ manufacture.
The product was developed in the USA and manufactured by American Nutritional Corp Inc.
After several months of development, the product has been manufactured in accordance to Cultech’s requirements for 5,000 units.
“First meaningful export for agreement”
Chief executive officer Sean Hall said: “This is our first meaningful export for this trade agreement and I see this as a start of great potential as we develop UK markets.”
Magnesium (Mg) has well-known benefits for stress reduction, sleep, and mitigating restless legs.
Mg Optima Relax as a nutraceutical (that being with no CBD) is well placed in the Australian marketplace as a Medlab nutraceutical.
The combination of the two formulations (Mg Optima Relax and CBD) adds to the overall story of promoting relaxation and reducing stress.
Hall continued: “This product is not for Australia because of our laws relating to CBD use, but primed for other global legal markets.
“We would envisage a more global play regarding this product, as most Westerners are well versed in the benefits of magnesium, and hence its relatively easy to understand the synergistic benefits of combining magnesium and CBD.”
Shares are up 7% to 15 cents.